UNITED THERAPEUTICS CORP (UTHR:NASDAQ)
$516.68 -1.85 (-0.3568%)
Analysed UNITED THERAPEUTICS CORP (UTHR:NASDAQ) News Sources
Will LQDA's Differentiated PAH Approach Drive Growth?
24-08-2026
yahoo.com
3 Cash-Producing Stocks We Keep Off Our Radar
26-08-2026
yahoo.com
Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat
12-08-2026
yahoo.com
FDA extends review of Capricor cell therapy; Pain drug startup to go public
24-08-2026
biopharmadive.com
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript
12-08-2026
fool.com
BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ...
12-08-2026
yahoo.com
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
24-08-2026
yahoo.com
United Therapeutics Ralinepag NDA Accepted by FDA With June 2027 Decision Date
24-08-2026
advfn.com
United Therapeutics (UTHR) Stock Looks Undervalued Following TETON PPF Enrollment News
24-08-2026
yahoo.com
Why United Therapeutics (UTHR) Is Getting Attention Today
25-08-2026
yahoo.com
What is the current price of UNITED THERAPEUTICS CORP (UTHR:NASDAQ)?
The current price of UNITED THERAPEUTICS CORP (UTHR:NASDAQ) is $516.68.
UNITED THERAPEUTICS CORP (UTHR:NASDAQ) absolute price change since previous trading day?
The absolute price change of UNITED THERAPEUTICS CORP (UTHR:NASDAQ) since the previous trading day is $-1.85.
UNITED THERAPEUTICS CORP (UTHR:NASDAQ) percentage price change since previous trading day?
The percentage price change of UNITED THERAPEUTICS CORP (UTHR:NASDAQ) since the previous trading day is -0.3568%.
What is the most recent average sentiment score for UNITED THERAPEUTICS CORP (UTHR:NASDAQ)?
The most recent average sentiment score for UNITED THERAPEUTICS CORP (UTHR:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for UNITED THERAPEUTICS CORP (UTHR:NASDAQ)?
The most recent sentiment for UNITED THERAPEUTICS CORP (UTHR:NASDAQ) is .
SEC-8K** Filing Available For UNITED THERAPEUTICS CORP (UTHR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.